Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis C

  Free Subscription


26.08.2019

1 BMC Gastroenterol
1 Dig Dis Sci
1 Eur J Gastroenterol Hepatol
1 Hepatology
2 J Gen Virol
2 J Hepatol
3 J Viral Hepat
2 PLoS One
1 Scand J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Gastroenterol

  1. MIDORIKAWA Y, Takayama T, Nakayama H, Higaki T, et al
    Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma.
    BMC Gastroenterol. 2019;19:147.
    PubMed     Text format     Abstract available


    Dig Dis Sci

  2. FELD JJ, Krassenburg LAP
    What Comes First: Treatment of Viral Hepatitis or Liver Cancer?
    Dig Dis Sci. 2019 Mar 14. pii: 10.1007/s10620-019-05518.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  3. DURCAN E, Hatemi I, Sonsuz A, Canbakan B, et al
    The effect of direct antiviral treatment on the depression, anxiety, fatigue and quality-of-life in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Aug 20. doi: 10.1097/MEG.0000000000001501.
    PubMed     Text format     Abstract available


    Hepatology

  4. JOHIRA Y, Hatooka H, Mori N, Fukuhara T, et al
    Regression of idiopathic thrombocytopenic purpura in a patient with eradication of hepatitis C virus by direct-acting antivirals.
    Hepatology. 2019 Aug 20. doi: 10.1002/hep.30900.
    PubMed     Text format     Abstract available


    J Gen Virol

  5. BEECH H
    Expression of concern: Hepatitis C virus activates interleukin-1beta via caspase-1-inflammasome complex.
    J Gen Virol. 2019 Aug 23. doi: 10.1099/jgv.0.001313.
    PubMed     Text format    

  6. BEECH H
    Expression of concern: Activation of transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway.
    J Gen Virol. 2019 Aug 20. doi: 10.1099/jgv.0.001312.
    PubMed     Text format    


    J Hepatol

  7. ROSSI C, Jeong D, Wong S, McKee G, et al
    Sustained Virologic Response from Interferon-based Hepatitis C regimes IS associated with Reduced risk of Extrahepatic Manifestations.
    J Hepatol. 2019 Aug 6. pii: S0168-8278(19)30462.
    PubMed     Text format     Abstract available

  8. DEGASPERI E, Spinetti A, Lombardi A, Landonio S, et al
    Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure.
    J Hepatol. 2019 Aug 6. pii: S0168-8278(19)30461.
    PubMed     Text format     Abstract available


    J Viral Hepat

  9. JACKA B, Roy E, Hoj S, Minoyan N, et al
    Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada.
    J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13194.
    PubMed     Text format     Abstract available

  10. ROSA-HEZODE I, Chousterman M, Costes L, Labourdette C, et al
    Cascade of care for migrants tested Hepatitis C antibodies positive in France through a systematic screening program: the PRECAVIR study.
    J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13192.
    PubMed     Text format     Abstract available

  11. TSAI MC, Lin CY, Hung CH, Lu SN, et al
    Evolution of Renal function under directly acting antivirals treatment for chronic hepatitis C: A real world experience.
    J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13193.
    PubMed     Text format     Abstract available


    PLoS One

  12. PUGA MAM, Bandeira LM, Pompilio MA, Rezende GR, et al
    Screening for HBV, HCV, HIV and syphilis infections among bacteriologically confirmed tuberculosis prisoners: An urgent action required.
    PLoS One. 2019;14:e0221265.
    PubMed     Text format     Abstract available

  13. KWO PY, Puenpatom A, Zhang Z, Hui SL, et al
    Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.
    PLoS One. 2019;14:e0218759.
    PubMed     Text format     Abstract available


    Scand J Gastroenterol

  14. KJELLIN M, Kileng H, Akaberi D, Palanisamy N, et al
    Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway.
    Scand J Gastroenterol. 2019 Aug 19:1-9. doi: 10.1080/00365521.2019.1652846.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: